by
Loren Bonner, DOTmed News Online Editor | August 27, 2013
A new radioactive diagnostic imaging agent used to help doctors with the staging and management of breast and melanoma cancer patients has just been issued pass-through "C" coding.
According to Navidea Biopharmaceuticals, Inc., the company that makes the agent, the coding will streamline the billing and reimbursement process for hospital providers who use the agent and support its fair and equitable reimbursement.
The new drug, technetium Tc 99m tilmanocept (Lymphoseek), was
approved by the U.S. Food and Drug Administration in March. According to experts, it will give doctors a more accurate way to find the sentinel lymph node, and in turn, help them determine where the patient's cancer has spread.
Ad Statistics
Times Displayed: 174484
Times Visited: 3183 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
The arrival of Lymphoseek is a testament to the advancements in molecular imaging that have taken place in the past 10 to 15 years. In contrast to previous lymph node mapping agents, Lymphoseek is a receptor-based agent that targets receptors on the surface of the lymphatic cells.
The new billing code will become effective on October 1, 2013.
